Abstract Aim Over recent years, [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced prostate cancer. Especially for alpha particle emitter treatments, there is still a need for improving dosimetry, which requires accurate values of relative biological effectiveness (RBE). To achieve that, consideration of DNA damages in the cell nucleus and knowledge of the energy deposition in the location of the DNA at the nanometer scale are required. Monte Carlo particle track structure simulations provide access to interactions at this level. The aim of this study was to estimate the RBE of 225Ac compared to 177Lu. The initial damage distribution after radionuclide decay and the residu...
International audienceThe aim of this study is to build a simulation framework to evaluate the numbe...
The good efficacy of radioligand therapy (RLT) targeting prostate specific-membrane antigen (PSMA) f...
One promising treatment option for metastatic castration-resistant prostate cancer is systemic radio...
The growing number of particle therapy facilities worldwide landmarks a novel era of precision oncol...
Targeted α-therapy (TAT) could be delivered early to patients who are at a high-risk for developing ...
In radiopharmaceutical treatmentsα-particles are employed to treat tumor cells. However, the mechani...
Background: The development of new targeted alpha therapies motivates improving alpha particle dosim...
International audienceBackground/Aim : The growing use of hadrons in oncology entails the need to es...
Diffusing alpha-emitters radiation Therapy (DaRT) is an interstitial brachytherapy technique using 2...
The overarching goal of this thesis is to establish a well-characterized platform to investigate the...
International audienceBackground: In the context of predicting biological effects in Targeted Alpha ...
International audienceIn the context of predicting biological effects in Targeted Alpha Therapy (TAT...
International audienceThe TOPAS Monte Carlo (MC) system is used in radiation therapy and medical ima...
Background: The use of protons was first suggested for use in treating cancer in 1946, due to its pr...
IntroductionRadium-223 (223Ra) has been shown to have an overall survival benefit in metastatic cast...
International audienceThe aim of this study is to build a simulation framework to evaluate the numbe...
The good efficacy of radioligand therapy (RLT) targeting prostate specific-membrane antigen (PSMA) f...
One promising treatment option for metastatic castration-resistant prostate cancer is systemic radio...
The growing number of particle therapy facilities worldwide landmarks a novel era of precision oncol...
Targeted α-therapy (TAT) could be delivered early to patients who are at a high-risk for developing ...
In radiopharmaceutical treatmentsα-particles are employed to treat tumor cells. However, the mechani...
Background: The development of new targeted alpha therapies motivates improving alpha particle dosim...
International audienceBackground/Aim : The growing use of hadrons in oncology entails the need to es...
Diffusing alpha-emitters radiation Therapy (DaRT) is an interstitial brachytherapy technique using 2...
The overarching goal of this thesis is to establish a well-characterized platform to investigate the...
International audienceBackground: In the context of predicting biological effects in Targeted Alpha ...
International audienceIn the context of predicting biological effects in Targeted Alpha Therapy (TAT...
International audienceThe TOPAS Monte Carlo (MC) system is used in radiation therapy and medical ima...
Background: The use of protons was first suggested for use in treating cancer in 1946, due to its pr...
IntroductionRadium-223 (223Ra) has been shown to have an overall survival benefit in metastatic cast...
International audienceThe aim of this study is to build a simulation framework to evaluate the numbe...
The good efficacy of radioligand therapy (RLT) targeting prostate specific-membrane antigen (PSMA) f...
One promising treatment option for metastatic castration-resistant prostate cancer is systemic radio...